// App-Quantinova.ai

2037 : Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.

Researchers

Presenter

  • Lakshmi Nayak

Principal Investigators

  • Sarah C. Gaffey

  • Katherine B. Peters

  • Jennifer Leigh Clarke

  • Justin T Jordan

  • John Frederick De Groot

  • Phioanh Leia Nghiemphu

  • Thomas Joseph Kaley

  • Howard Colman

  • Terri Armstrong

  • Martin J. Taphoorn

  • Victoria Caruso

  • Myriam Bednarek Debruyne

  • Chinmay Bhavsar

  • Annette M Molinaro

  • Mariano Severgnini

  • Patrick Y. Wen

  • David A. Reardon

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Women's Hospital, Brookline, MA

  • Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA

  • Duke University Medical Center, Durham, NC

  • University of California, San Francisco, San Francisco, CA

  • Massachusetts General Hospital, Boston, MA

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • University of California, Los Angeles, Los Angeles, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • National Cancer Institute, Bethesda, MD

  • Haaglanden Medical Center, The Hague, Netherlands

  • UC San Francisco, San Francisco, CA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT02337491

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved